Jump to content

Picoplatin: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
m +cat
Citation bot (talk | contribs)
Add: pages, issue. Removed parameters. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 305/373
 
(44 intermediate revisions by 29 users not shown)
Line 1: Line 1:
{{chembox
{{deadend|date=October 2009}}
| Verifiedfields = changed
'''Picoplatin''' is a cytotoxic platinum compound in clinical development by Poniard Pharmaceuticals, Inc. for the treatment of patients with solid tumors.
| Watchedfields = changed
| verifiedrevid = 444934628
| ImageFile = Picoplatin.png
| ImageSize = 150px
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride
| OtherNames =
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = B5TAN0L720
| CASNo_Ref = {{cascite|correct|??}}
| CASNo = 181630-15-9
| PubChem = 177358
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 154428
| SMILES = Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
| SMILES_Comment = ionic form
| SMILES1 = Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
| SMILES1_Comment = coordination form
| InChI = 1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
| InChIKey = IIMIOEBMYPRQGU-NUQVWONBAG
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = IIMIOEBMYPRQGU-UHFFFAOYSA-L
}}
|Section2={{Chembox Properties
| C=6 | H=10 | Cl=2 | N=2 | Pt=1
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = }}
|Section3={{Chembox Hazards
| MainHazards =
| FlashPt =
| AutoignitionPt = }}
}}

'''Picoplatin''' is a [[platinum-based antineoplastic agent]] in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid [[tumor]]s.<ref>{{cite journal | doi = 10.1039/C0DT00292E | volume=39 | title=The status of platinum anticancer drugs in the clinic and in clinical trials | year=2010 | journal=Dalton Transactions | last1 = Wheate | first1 = Nial J.| issue=35 | pages=8113–8127 | url=https://ses.library.usyd.edu.au/bitstream/2123/9269/2/41%20Dalton%20perspective.pdf | pmid=20593091 | hdl=2123/14271 | hdl-access=free }}</ref>

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>[http://www.poniard.com/programs/picoplatin/clinical.html Picoplatin Clinical Results], Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced [[small cell lung cancer]].<ref>[http://www.fiercebiotech.com/story/breaking-news-poniard-shares-crash-phiii-picoplatin-failure/2009-11-16 Poniard shares crash on Phase III picoplatin failure], fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic [[colorectal cancer]].<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref>


== References ==
== References ==
<!--- See [[Wikipedia:Footnotes]] on how to create references using <ref></ref> tags which will then appear here automatically -->
{{Reflist}}
{{Reflist}}
{{Platinum compounds}}


[[Category:Platinum(II) compounds]]
== External links ==
[[Category:Organochlorides]]
* [http://www.poniard.com/ www.poniard.com]
[[Category:Pyridines]]
[[Category:Platinum-based antineoplastic agents]]


[[Category:Antineoplastic drugs]]
[[Category:Articles created via the Article Wizard]]


{{drug-stub}}
{{antineoplastic-drug-stub}}

Latest revision as of 17:10, 1 June 2022

Picoplatin
Names
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.205.233 Edit this at Wikidata
UNII
  • InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 ☒N
    Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L ☒N
  • InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
    Key: IIMIOEBMYPRQGU-NUQVWONBAG
  • ionic form: Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
  • coordination form: Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
Properties
C6H10Cl2N2Pt
Molar mass 376.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]

References

[edit]
  1. ^ Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
  2. ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
  3. ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
  4. ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009